Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
Investing.com - BofA Securities has reiterated its Underperform rating and $14.00 price target on Pharvaris B.V. (NASDAQ:PHVS), currently trading at $18.68, as the company announced updated timelines for its hereditary angioedema (HAE) therapy. According to InvestingPro data, analysts’ price targets range from $14.73 to $56.46, with 4 analysts recently revising their earnings estimates upward.
Pharvaris revealed that topline data from its ongoing RAPIDe-3 pivotal phase 3 study evaluating deucrictibant as an on-demand therapy for HAE is expected in the fourth quarter of 2025. If the data proves positive, the company plans to submit a New Drug Application (NDA) in the first half of 2026. InvestingPro analysis shows the company holds more cash than debt, with a strong current ratio of 11.1, though it’s currently burning through cash rapidly.
BofA Securities currently models peak penetration for deucrictibant at 20% of the addressable market and notes that Kalvista’s Ekterly was recently approved as the first oral on-demand HAE therapy, giving it at least 12 months of market exclusivity before Pharvaris could potentially enter the market.
The investment bank plans to survey key opinion leaders ahead of the topline data to better understand what level of results would differentiate deucrictibant and potentially disrupt the established HAE market.
BofA Securities maintains its cautious stance on Pharvaris as it continues to assess the company’s competitive positioning in the HAE treatment landscape.
In other recent news, Pharvaris has shared significant updates regarding its oral bradykinin B2 receptor antagonist, deucrictibant, aimed at treating hereditary angioedema (HAE). The company presented data at the European Academy of Allergy and Clinical Immunology Congress 2025, highlighting sustained attack reduction and quality of life improvements in the CHAPTER-1 study. Additionally, the RAPIDe-2 study demonstrated early symptom relief, with a median time of 1.1 hours and complete resolution in 86.9% of HAE attacks within 24 hours. Pharvaris is also conducting Phase 3 studies, CHAPTER-3 and RAPIDe-3, to evaluate the drug’s efficacy for prevention and on-demand treatment, respectively.
Citizens JMP analysts have reiterated their Market Outperform rating for Pharvaris, maintaining a price target of $55. This follows the company’s announcement of plans to initiate a new Phase 3 trial for deucrictibant in acquired angioedema. JMP Securities also maintained a Market Outperform rating, emphasizing the anticipated Phase 3 data for deucrictibant, expected in 2026. The analyst from JMP Securities highlighted potential U.S. launches in 2027 for acute treatment and 2028 for prophylactic use, with projected peak sales estimates reaching $600 million and $1.6 billion, respectively. These developments underscore Pharvaris’s strategic positioning in the HAE market and its potential impact on the therapeutic landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.